

Note to readers with disabilities: *EHP* strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in *EHP* articles may not conform to [508 standards](#) due to the complexity of the information being presented. If you need assistance accessing journal content, please contact ehponline@niehs.nih.gov. Our staff will work with you to assess and meet your accessibility needs within 3 working days.

Supplemental Material

In Utero Exposure to Select Phenols and Phthalates and Respiratory Health in Five Year-Old Boys: A Prospective Study

Céline Vernet, Isabelle Pin, Lise Giorgis-Allemand, Claire Philippat, Meriem Benmerad, Joane Quentin, Antonia M. Calafat, Xiaoyun Ye, Isabella Annesi-Maesano, Valérie Siroux, Rémy Slama, and the EDEN mother-child cohort study group

Table of Contents

Table S1. Phthalates and associated urinary metabolites in the EDEN cohort.

Table S2. Spearman correlation between ln-transformed standardized phenol concentrations

Table S3. Spearman correlation between ln-transformed standardized phthalate metabolites concentrations.

Table S4. Adjusted associations between pregnancy phenols raw (non-standardized) concentrations and respiratory outcomes (n=587) and FEV₁% (n=228) in boys. Models additionally adjusted for creatinine.

Table S5. Adjusted associations between pregnancy phthalate metabolites raw (non-standardized) concentrations and respiratory outcomes (n=587) and FEV₁% (n=228) in boys. Models additionally adjusted for creatinine.

Table S6. Adjusted associations between pregnancy phenols standardized concentrations and respiratory outcomes (n=447) and FEV₁% (n=171) in boys from non-smoking mothers.

Table S7. Adjusted associations between pregnancy phthalate metabolites standardized concentrations and respiratory outcomes (n=447) and FEV₁% (n=171) in boys from non-smoking mothers.

Table S8. Adjusted associations between pregnancy phenols standardized concentrations and respiratory outcomes (n=470) and FEV₁% (n=185) in boys from non-asthmatic parents.

Table S9. Adjusted associations between pregnancy phthalate metabolites standardized concentrations and respiratory outcomes (n=470) and FEV₁% (n=185) in boys from non-asthmatic parents.

Table S10. Adjusted associations between pregnancy phenols standardized concentrations and respiratory outcomes (n=562) and FEV₁% (n=217) in full-term boys.

Table S11. Adjusted associations between pregnancy phthalate metabolites standardized concentrations and respiratory outcomes (n=562) and FEV₁% (n=217) in full-term boys.

Figure S1. Occurrence of doctor-diagnosed asthma (A), wheezing (B) and bronchiolitis/bronchitis (C), Kaplan-Meier estimates.

Table S1. Phthalates and associated urinary metabolites in the EDEN cohort

Parent compound	Abbreviation	Urinary metabolites	Abbreviation
Diethyl phthalate	DEP	Mono-ethyl phthalate	MEP
Di-n-butyl phthalate	DnBP	Mono-n-butyl phthalate	MnBP
Di-isobutyl phthalate	DiBP	Mono-isobutyl phthalate	MiBP
Di-n-octylphthalate	DNOP		
Di-n-butyl phthalate	DnBP		
Other high molecular weight phthalates	/	Mono-(3-carboxypropyl) phthalate	MCPP
Butylbenzyl phthalate	BBzP	Mono-benzyl phthalate	MBzP
Di-isodecyl phthalate	DIDP	Mono-(carboxynonyl) phthalate	MCNP
Di-isononyl phthalate	DINP	Mono(carboxyoctyl) phthalate	MCOP
Di-2-ethylhexyl phthalate	DEHP	Mono-(2-ethyl-5-hydroxyhexyl) phthalate Mono-(2-ethyl-5-oxohexyl) phthalate Mono-(2-ethyl-5-carboxypentyl) phthalate Mono-2-ethylhexyl phthalate	MEHHP MEOHP MECPP MEHP

Table S2. Spearman correlation between ln-transformed standardized^a phenol concentrations

	2,4-DCP	2,5-DCP	Σ 2-DCP	BPA	BP3	TCS	MP	EP	PP	BP	Σ PB
2,4-DCP	1.00										
2,5-DCP	0.82	1.00									
Σ 2-DCP	0.86	1.00	1.00								
BPA	0.01	0.05	0.05	1.00							
BP3	0.06	0.04	0.04	0.03	1.00						
TCS	0.13	-0.11	-0.08	-0.05	0.01	1.00					
MP	-0.02	-0.09	-0.08	0.07	0.20	0.15	1.00				
EP	0.08	-0.04	-0.02	-0.03	0.15	0.16	0.55	1.00			
PP	0.00	-0.07	-0.06	0.00	0.12	0.22	0.81	0.49	1.00		
BP	0.03	-0.11	-0.09	0.00	0.16	0.23	0.55	0.68	0.53	1.00	
Σ PB	-0.01	-0.09	-0.08	0.05	0.19	0.17	0.99	0.59	0.84	0.58	1.00

2,4-DCP = 2,4-Dichlorophenol; 2,5-DCP = 2,5-Dichlorophenol; Σ 2-DCP = molar sum of 2-Dichlorophenols (2,4-DCP, 2,5-DCP); BPA = Bisphenol A; BP3 = Benzophenone-3; TCS = Triclosan; MP = Methyl-paraben; EP = Ethyl-paraben; PP = Propyl-paraben; BP = Butyl-paraben; Σ PB = molar sum of parabens (MP, EP, PP, BP).

^a Standardized for urine sampling conditions (creatinine level, day and hour of sampling, gestational age, storage duration at room temperature and year of analysis), as detailed in *Mortamais et al.* (2012).

Table S3. Spearman correlation between ln-transformed standardized^a phthalate metabolites concentrations

	Σ LMW	MEP	MnBP	MiBP	Σ HMW	MCPP	MBzP	MCNP	MCOP	MEHHP	MEOHP	MECPP	MEHP	Σ DEHP
Σ LMW	1.00													
MEP	0.78	1.00												
MnBP	0.59	0.08	1.00											
MiBP	0.33	0.03	0.39	1.00										
Σ HMW	0.16	0.00	0.33	0.37	1.00									
MCPP	0.41	0.04	0.64	0.24	0.31	1.00								
MBzP	0.27	0.12	0.37	0.43	0.57	0.23	1.00							
MCNP	0.05	0.03	0.06	0.10	0.28	0.29	0.13	1.00						
MCOP	0.06	0.02	0.06	0.12	0.44	0.23	0.25	0.44	1.00					
MEHHP	0.11	0.01	0.25	0.31	0.93	0.21	0.38	0.21	0.35	1.00				
MEOHP	0.11	0.00	0.26	0.35	0.95	0.23	0.41	0.22	0.37	0.98	1.00			
MECPP	0.03	-0.04	0.18	0.26	0.93	0.18	0.32	0.23	0.37	0.94	0.95	1.00		
MEHP	0.10	-0.01	0.22	0.36	0.83	0.19	0.38	0.16	0.33	0.82	0.84	0.80	1.00	
Σ DEHP	0.08	-0.02	0.23	0.31	0.95	0.20	0.37	0.22	0.36	0.98	0.99	0.98	0.86	1.00

Σ LMW = molar sum of Low Molecular Weight phthalates (MEP, MnBP, MiBP); MEP = Monoethyl phthalate; MnBP = Mono-n-butyl phthalate; MiBP = Mono-isobutyl phthalate; Σ HMW = molar sum of High Molecular Weight phthalates (MCPP, MBzP, MCNP, MCOP, MEHHP, MEOHP, MECPP, MEHP); MCPP = Mono (3-carboxypropyl) phthalate; MBzP = Monobenzyl phthalate; MCNP = Mono-(carboxynonyl) phthalate, MCOP = Monocarboxy-isoctyl phthalate; MEHHP = Mono(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP = Mono(2-ethyl-5-oxohexyl) phthalate; MECPP = Mono(2-ethyl-5-carboxypentyl) phthalate; MEHP = Mono(2-ethylhexyl) phthalate; Σ DEHP = molar sum of di(2-ethylhexyl) phthalate metabolites (MEHHP, MEOHP, MECPP, MEHP).

^a Standardized for urine sampling conditions (creatinine level, day and hour of sampling, gestational age, storage duration at room temperature and year of analysis), as detailed in Mortamais *et al.* (2012).

Table S4. Adjusted associations between pregnancy phenols raw (non-standardized) concentrations and respiratory outcomes (n=587) and FEV₁% (n=228) in boys. Models additionally adjusted for creatinine.

Phenol ^c	Wheezing (until age 5y) ^a			Asthma diagnosis (until age 5y) ^a			Bronchiolitis/Bronchitis (until age 3y) ^a			FEV ₁ % ^b		
	N = 587			N = 587			N = 587			N = 228		
	HR (95% CI)	p _{het} ^e	p-value		HR (95% CI)	p _{het} ^e	p-value		HR (95% CI)	p _{het} ^e	p-value	
2,4-Dichlorophenol												
Continuous ^d	1.06 (0.95, 1.18)		0.27	1.02 (0.87, 1.20)		0.79		0.98 (0.89, 1.08)		0.69		
T1	1.00		0.31	1.00		0.85		1.00		0.93		
T2	0.89 (0.64, 1.22)			0.94 (0.58, 1.52)				1.00 (0.78, 1.29)				
T3	1.13 (0.83, 1.55)			1.08 (0.67, 1.74)				0.96 (0.74, 1.24)				
2,5-Dichlorophenol												
Continuous ^d	1.08 (1.00, 1.16)		0.04	1.04 (0.93, 1.16)		0.53		1.00 (0.94, 1.07)		0.97		
T1	1.00		0.02	1.00		0.22		1.00		0.84		
T2	1.57 (1.14, 2.16)			1.51 (0.94, 2.42)				1.06 (0.82, 1.37)				
T3	1.38 (1.00, 1.91)			1.37 (0.85, 2.23)				1.07 (0.84, 1.38)				
ΣDichlorophenols												
Continuous ^d	1.08 (1.00, 1.17)		0.05	1.04 (0.92, 1.17)		0.56		1.00 (0.94, 1.07)		1.00		
T1	1.00		0.02	1.00		0.17		1.00		0.67		
T2	1.59 (1.15, 2.19)			1.57 (0.97, 2.53)				1.09 (0.85, 1.41)				
T3	1.39 (1.00, 1.93)			1.39 (0.85, 2.27)				1.12 (0.87, 1.44)				
Bisphenol A												
Continuous ^d	0.98 (0.83, 1.15)		0.77	1.21 (0.96, 1.53)		0.11		1.13 (0.99, 1.30)		0.07		
T1	1.00		0.14	1.00		0.51		1.00		0.11		
T2	1.33 (0.97, 1.82)			1.30 (0.79, 2.14)				1.27 (0.98, 1.63)				
T3	1.05 (0.74, 1.49)			1.32 (0.79, 2.19)				1.29 (0.99, 1.70)				
Benzophenone-3												
Continuous ^d	0.94 (0.87, 1.01)		0.10	0.96 (0.85, 1.07)		0.46		0.99 (0.93, 1.05)		0.82		
T1	1.00		0.14	1.00		0.15		1.00		0.73		
T2	0.96 (0.71, 1.30)			0.67 (0.43, 1.07)				0.98 (0.77, 1.25)				
T3	0.74 (0.54, 1.02)			0.68 (0.42, 1.09)				0.91 (0.70, 1.17)				
Triclosan												
Continuous ^d	0.98 (0.94, 1.03)		0.50	0.99 (0.92, 1.07)		0.86		0.99 (0.96, 1.03)		0.79		
T1	1.00		0.74	1.00		0.83		1.00		0.95		
T2	0.89 (0.65, 1.21)			1.13 (0.72, 1.77)				0.97 (0.76, 1.24)				
T3	0.93 (0.69, 1.25)			1.00 (0.63, 1.60)				0.96 (0.76, 1.23)				
Methyl-paraben												
Continuous ^d	0.93 (0.85, 1.00)		0.06	0.99 (0.88, 1.12)		0.91		0.94 (0.88, 1.00)		0.05		
T1	1.00		0.11	1.00		0.56		1.00		0.02		
T2	0.75 (0.55, 1.02)			1.23 (0.78, 1.95)				0.82 (0.65, 1.05)				
T3	0.76 (0.56, 1.04)			0.99 (0.60, 1.62)				0.68 (0.53, 0.89)				
Ethyl-paraben												
Continuous ^d	1.01 (0.96, 1.08)		0.63	1.09 (1.00, 1.20)		0.06		0.99 (0.94, 1.03)		0.56		
T1	1.00		0.82	1.00		0.18		1.00		0.02		
T2	0.98 (0.71, 1.34)			1.51 (0.93, 2.44)				1.22 (0.96, 1.56)				
T3	1.07 (0.78, 1.48)			1.51 (0.91, 2.51)				0.87 (0.67, 1.13)				
Propyl-paraben												
Continuous ^d	0.96 (0.90, 1.02)		0.18	0.98 (0.89, 1.08)		0.71		0.96 (0.91, 1.01)		0.09		
T1	1.00		0.53	1.00		0.43		1.00		0.03		
T2	0.91 (0.67, 1.23)			1.19 (0.75, 1.86)				0.77 (0.61, 0.99)				
T3	0.84 (0.61, 1.14)			0.87 (0.53, 1.42)				0.73 (0.57, 0.94)				
Butyl-paraben												
Continuous ^d	0.98 (0.92, 1.04)		0.54	1.00 (0.91, 1.10)		0.98		0.97 (0.93, 1.02)		0.29		
T1	1.00		0.43	1.00		1.00		1.00		0.003		
T2	1.01 (0.75, 1.37)			1.02 (0.64, 1.61)				1.15 (0.90, 1.46)				
T3	0.84 (0.61, 1.16)			1.00 (0.61, 1.63)				0.75 (0.58, 0.97)				
ΣParabens												
Continuous ^d	0.93 (0.86, 1.00)		0.06	0.99 (0.88, 1.12)		0.93		0.94 (0.88, 1.00)		0.06		
T1	1.00		0.13	1.00		0.34		1.00		0.02		
T2	0.83 (0.62, 1.13)			1.27 (0.81, 2.00)				0.90 (0.71, 1.14)				
T3	0.72 (0.52, 0.99)			0.92 (0.55, 1.52)				0.69 (0.53, 0.89)				

HR = hazard ratio; FEV₁% = forced expiratory volume in 1 second expressed in percent predicted; CI = confidence interval; ΣDichlorophenols = molar sum of 2-Dichlorophenols (2,4-, 2,5-dichlorophenols); ΣParabens = molar sum of parabens (Methyl-, Ethyl-, Propyl-, Butyl-parabens).

^a Models adjusted for creatinine, centre, residence area, parental history of asthma or allergies, maternal ethnicity, maximal parental education level, maternal or passive smoking during pregnancy, postnatal passive smoking, older siblings, day-care. Missing values in covariates were imputed for at least one covariate in 277 boys, using the MICE multiple imputation method (100 imputations were performed). ^b additionally adjusted for child's height and age.

^c Crude concentrations.

^d Estimates for 1 unit increase in ln-transformed standardized concentration.

^e p-values of heterogeneity test.

Italicized p-values are p-values of monotonic trend test.

Table S5. Adjusted associations between pregnancy phthalate metabolites raw (non-standardized) concentrations and respiratory outcomes (n=587) and FEV₁% (n=228) in boys.

Models additionally adjusted for creatinine.

Phthalate ^c	Wheezing (until age 5y) ^a			Asthma diagnosis (until age 5y) ^a			Bronchiolitis/Bronchitis (until age 3y) ^a			FEV ₁ % ^b		
	N = 587			N = 587			N = 587			N = 228		
	HR (95% CI)	p _{het} ^e	p-value	HR (95% CI)	p _{het} ^e	p-value	HR (95% CI)	p _{het} ^e	p-value	beta (95% CI)	p _{het} ^e	p-value
ΣLMW												
Continuous ^d	0.97 (0.84, 1.12)			0.97 (0.78, 1.21)			1.00 (0.89, 1.12)			-0.43 (-2.14, 1.27)		
T1	1.00	0.80	0.86	1.00	0.94	0.75	1.00	0.71	0.72	0.00	0.16	0.62
T2	1.10 (0.79, 1.52)			0.94 (0.58, 1.52)			0.92 (0.71, 1.19)			0.35 (-3.23, 3.92)		
T3	1.01 (0.71, 1.43)			0.91 (0.54, 1.53)			1.01 (0.77, 1.34)			-3.00 (-6.96, 0.96)		
MEP												
Continuous ^d	0.99 (0.88, 1.11)			1.03 (0.87, 1.22)			1.02 (0.94, 1.12)			-0.10 (-1.45, 1.24)		
T1	1.00	0.87	0.80	1.00	0.99	0.90	1.00	0.75	0.99	0.00	0.67	0.88
T2	1.07 (0.77, 1.47)			0.99 (0.61, 1.60)			1.10 (0.85, 1.42)			0.87 (-2.65, 4.39)		
T3	0.99 (0.71, 1.38)			1.02 (0.62, 1.69)			1.04 (0.80, 1.36)			-0.77 (-4.72, 3.19)		
MnBP												
Continuous ^d	1.03 (0.92, 1.16)			1.00 (0.83, 1.19)			0.98 (0.89, 1.07)			-0.35 (-1.69, 0.99)		
T1	1.00	0.64	0.36	1.00	0.64	0.89	1.00	0.69	0.98	0.00	0.41	0.61
T2	1.01 (0.73, 1.40)			1.23 (0.76, 1.96)			0.90 (0.69, 1.16)			1.47 (-2.13, 5.09)		
T3	1.15 (0.81, 1.64)			1.04 (0.61, 1.79)			0.96 (0.73, 1.28)			-0.89 (-4.89, 3.11)		
MiBP												
Continuous ^d	0.98 (0.84, 1.14)			1.03 (0.81, 1.30)			1.02 (0.90, 1.16)			-1.34 (-3.02, 0.34)		
T1	1.00	0.28	0.22	1.00	0.36	0.47	1.00	0.92	0.96	0.00	0.14	0.12
T2	0.90 (0.65, 1.25)			0.78 (0.48, 1.27)			0.95 (0.74, 1.22)			0.53 (-3.07, 4.14)		
T3	1.17 (0.83, 1.66)			1.11 (0.65, 1.87)			0.99 (0.75, 1.31)			-3.01 (-7.05, 1.03)		
ΣHMW												
Continuous ^d	1.05 (0.90, 1.23)			1.14 (0.90, 1.45)			0.90 (0.79, 1.03)			-1.26 (-3.06, 0.55)		
T1	1.00	0.07	0.21	1.00	0.13	0.20	1.00	0.12	0.09	0.00	0.09	0.03
T2	1.46 (1.05, 2.03)			1.64 (1.00, 2.69)			1.05 (0.82, 1.36)			-0.36 (-3.97, 3.24)		
T3	1.36 (0.95, 1.93)			1.57 (0.91, 2.68)			0.81 (0.61, 1.08)			-4.03 (-8.08, -0.02)		
MCPP												
Continuous ^d	1.03 (0.89, 1.20)			0.98 (0.77, 1.24)			0.90 (0.80, 1.02)			-0.49 (-2.32, 1.35)		
T1	1.00	0.55	0.28	1.00	0.20	0.94	1.00	0.77	0.92	0.00	0.15	0.87
T2	1.08 (0.78, 1.49)			1.50 (0.93, 2.41)			0.91 (0.70, 1.18)			-3.59 (-7.19, 0.01)		
T3	1.21 (0.86, 1.69)			1.13 (0.65, 1.94)			0.96 (0.73, 1.26)			-2.00 (-5.89, 1.90)		
MBzP												
Continuous ^d	0.98 (0.86, 1.11)			1.17 (0.97, 1.41)			0.97 (0.87, 1.07)			-0.23 (-1.73, 1.25)		
T1	1.00	0.87	0.63	1.00	0.14	0.12	1.00	0.28	0.84	0.00	0.82	0.75
T2	0.96 (0.71, 1.37)			1.51 (0.91, 2.49)			1.22 (0.94, 1.58)			-1.20 (-4.94, 2.54)		
T3	1.07 (0.76, 1.51)			1.68 (0.98, 2.86)			1.06 (0.79, 1.40)			-0.79 (-4.79, 3.22)		
MCNP												
Continuous ^d	1.10 (0.98, 1.24)			1.15 (0.97, 1.36)			0.98 (0.89, 1.08)			0.51 (-0.90, 1.92)		
T1	1.00	0.05	0.02	1.00	0.20	0.07	1.00	0.62	0.56	0.00	0.12	0.48
T2	1.05 (0.76, 1.46)			1.14 (0.68, 1.89)			1.12 (0.87, 1.45)			-3.50 (-7.17, 0.17)		
T3	1.44 (1.03, 2.01)			1.54 (0.93, 2.55)			1.12 (0.86, 1.47)			-0.72 (-4.58, 3.15)		
MCOP												
Continuous ^d	1.03 (0.89, 1.20)			1.04 (0.84, 1.29)			1.08 (0.96, 1.22)			-1.17 (-2.77, 0.42)		
T1	1.00	0.84	0.78	1.00	0.75	0.71	1.00	0.86	0.87	0.00	0.64	0.15
T2	1.10 (0.80, 1.51)			1.20 (0.74, 1.93)			1.07 (0.83, 1.38)			-0.36 (-3.92, 3.20)		
T3	1.07 (0.77, 1.50)			1.14 (0.69, 1.90)			1.04 (0.79, 1.36)			-1.70 (-5.51, 2.10)		
MEHHP												
Continuous ^d	1.05 (0.91, 1.20)			1.07 (0.86, 1.32)			0.95 (0.85, 1.07)			-1.12 (-2.64, 0.40)		
T1	1.00	0.21	0.37	1.00	0.32	0.66	1.00	0.68	0.87	0.00	0.06	0.15
T2	1.34 (0.97, 1.85)			1.43 (0.89, 2.30)			1.10 (0.86, 1.42)			-3.14 (-6.61, 0.32)		
T3	1.25 (0.89, 1.75)			1.21 (0.72, 2.04)			1.01 (0.77, 1.32)			-4.49 (-8.30, -0.68)		
MEOHP												
Continuous ^d	1.05 (0.91, 1.21)			1.07 (0.86, 1.33)			0.93 (0.83, 1.04)			-1.42 (-2.98, 0.14)		
T1	1.00	0.27	0.24	1.00	0.55	0.72	1.00	0.77	0.48	0.00	0.25	0.09
T2	1.28 (0.92, 1.77)			1.30 (0.81, 2.10)			0.98 (0.76, 1.27)			-1.03 (-4.64, 2.57)		
T3	1.28 (0.91, 1.80)			1.17 (0.69, 1.98)			0.91 (0.70, 1.20)			-3.30 (-7.29, 0.69)		
MECPP												
Continuous ^d	1.07 (0.92, 1.25)			1.11 (0.88, 1.40)			0.92 (0.81, 1.05)			-1.38 (-3.08, 0.32)		
T1	1.00	0.30	0.57	1.00	0.41	0.62	1.00	0.84	0.55	0.00	0.32	0.11
T2	1.30 (0.93, 1.80)			1.40 (0.86, 2.27)			0.98 (0.76, 1.27)			-1.93 (-5.67, 1.81)		
T3	1.19 (0.84, 1.70)			1.25 (0.74, 2.14)			0.92 (0.70, 1.22)			-3.10 (-7.15, 1.96)		
MEHP												
Continuous ^d	1.01 (0.89, 1.14)			1.03 (0.85, 1.23)			0.92 (0.83, 1.01)			-1.02 (-2.33, 0.28)		
T1	1.00	0.43	0.90	1.00	0.62	0.45	1.00	0.52	0.64	0.00	0.27	0.17
T2	0.93 (0.67, 1.29)			0.92 (0.57, 1.49)			0.86 (0.67, 1.11)			0.23 (-3.33, 3.80)		
T3	1.14 (0.82, 1.58)			1.16 (0.72, 1.88)			0.91 (0.70, 1.19)			-3.10 (-6.25, 1.22)		
ΣDEHP												
Continuous ^d	1.05 (0.90, 1.22)			1.08 (0.86, 1.36)			0.92 (0.82, 1.04)			-1.38 (-3.02, 0.26)		
T1	1.00	0.09	0.33	1.00	0.23	0.60	1.00	0.94	0.78	0.00	0.24	0.19
T2	1.45 (1.04, 2.01)			1.52 (0.94, 2.47)			0.96 (0.74, 1.24)			-2.71 (-6.28, 0.87)		
T3	1.30 (0.92, 1.84)			1.29 (0.75, 2.20)			0.96 (0.73, 1.26)			-3.05 (-7.02, 0.91)		

HR = hazard ratio; FEV₁% = forced expiratory volume in 1 second expressed in percent predicted; CI = confidence interval; ΣLMW = molar sum of Low Molecular Weight phthalates (MEP, MnBP, MiBP); ΣHMW = molar sum of High Molecular Weight phthalates (MCPP, MBzP, MCNP, MCOP, MEHHP, MEOHP, MECPP, MEHP); ΣDEHP = molar sum of di(2-ethylhexyl) phthalate metabolites (MEHHP, MEOHP, MECPP, MEHP). Parent compounds and associated metabolites are detailed in Table S1 (Supplemental material).

^a Models adjusted for creatinine, centre, residence area, parental history of asthma or allergies, maternal ethnicity, maximal parental education level, maternal or passive smoking during pregnancy, postnatal passive smoking, older siblings, day-care. Missing values in covariates were imputed for at least one covariate in 277 boys, using the MICE multiple imputation method (100 imputations were performed) ^b additionally adjusted for child's height and age.

^c Crude concentrations.

^d Estimates for 1 unit increase in ln-transformed standardized concentration.

^e p-values of heterogeneity test.

Italicized p-values are p-values of monotonic trend test.

Table S6. Adjusted associations between pregnancy phenols standardized concentrations and respiratory outcomes (n=447) and FEV₁% (n=171) in boys from non-smoking mothers.

Phenol ^c	Wheezing (until age 5) ^a			Asthma diagnosis (until age 5) ^b			Bronchiolitis/Bronchitis (until age 3) ^a			FEV ₁ % ^b						
	HR (95% CI)	N = 447	p _{het} ^e	p-value	HR (95% CI)	N = 447	p _{het} ^e	p-value	HR (95% CI)	N = 447	p _{het} ^e	p-value	beta (95% CI)	N = 171	p _{het} ^e	p-value
2,4-Dichlorophenol																
Continuous ^d	1.04 (0.92, 1.18)		0.53		1.04 (0.86, 1.25)		0.72		0.95 (0.85, 1.06)		0.36		0.76 (-0.76, 2.28)		0.32	
T1	1.00	0.46	0.90		1.00	0.80	0.99		1.00	0.58	0.30		0.00	0.58	0.97	
T2	1.25 (0.88, 1.80)				1.19 (0.70, 2.02)				0.96 (0.72, 1.27)				2.23 (-2.14, 6.61)			
T3	1.11 (0.77, 1.59)				1.06 (0.62, 1.81)				0.86 (0.65, 1.14)				0.70 (-3.57, 4.97)			
2,5-Dichlorophenol																
Continuous ^d	1.06 (0.98, 1.16)		0.16		1.05 (0.92, 1.20)		0.46		0.98 (0.91, 1.05)		0.52		0.46 (-0.58, 1.51)		0.38	
T1	1.00	0.02	0.29		1.00	0.13	0.43		1.00	0.96	0.86		0.00	0.97	0.90	
T2	1.70 (1.17, 2.48)				1.76 (1.01, 3.05)				1.03 (0.77, 1.38)				0.54 (-3.79, 4.87)			
T3	1.46 (1.01, 2.12)				1.50 (0.86, 2.62)				0.99 (0.74, 1.32)				0.43 (-3.84, 4.70)			
ΣDichlorophenols																
Continuous ^d	1.06 (0.97, 1.16)		0.19		1.05 (0.91, 1.20)		0.52		0.97 (0.90, 1.05)		0.48		0.51 (-0.58, 1.60)		0.36	
T1	1.00	0.11	0.43		1.00	0.11	0.54		1.00	0.92	1.00		0.00	0.97	0.99	
T2	1.48 (1.02, 2.15)				1.80 (1.04, 3.12)				1.06 (0.79, 1.42)				0.52 (-3.77, 4.80)			
T3	1.32 (0.92, 1.91)				1.45 (0.83, 2.54)				1.02 (0.77, 1.36)				0.16 (-4.10, 4.42)			
Bisphenol A																
Continuous ^d	1.02 (0.83, 1.24)		0.87		1.23 (0.93, 1.62)		0.15		1.16 (0.98, 1.37)		0.08		-0.25 (-2.43, 1.93)		0.82	
T1	1.00	0.70	0.43		1.00	0.26	0.10		1.00	0.38	0.20		0.00	0.60	0.35	
T2	1.11 (0.77, 1.59)				1.14 (0.63, 2.05)				1.00 (0.75, 1.33)				-1.92 (-6.12, 2.28)			
T3	1.17 (0.81, 1.69)				1.54 (0.89, 2.66)				1.19 (0.89, 1.58)				-1.86 (-6.18, 2.46)			
Benzophenone-3																
Continuous ^d	0.95 (0.87, 1.04)		0.29		1.00 (0.88, 1.14)		0.99		0.99 (0.93, 1.07)		0.88		-0.58 (-1.60, 0.44)		0.26	
T1	1.00	0.11	0.15		1.00	0.14	0.52		1.00	0.94	0.75		0.00	0.36	0.40	
T2	0.75 (0.53, 1.07)				0.59 (0.35, 1.02)				0.98 (0.74, 1.31)				-2.59 (-6.81, 1.62)			
T3	0.69 (0.48, 1.00)				0.69 (0.40, 1.16)				0.95 (0.71, 1.27)				-2.73 (-6.97, 1.51)			
Triclosan																
Continuous ^d	0.99 (0.94, 1.05)		0.78		0.99 (0.91, 1.08)		0.79		1.01 (0.96, 1.05)		0.77		0.08 (-0.61, 0.76)		0.83	
T1	1.00	0.77	0.48		1.00	0.71	0.44		1.00	0.53	0.71		0.00	0.92	0.69	
T2	0.96 (0.68, 1.37)				1.06 (0.64, 1.75)				1.16 (0.87, 1.53)				-0.03 (-4.18, 4.12)			
T3	0.88 (0.62, 1.25)				0.84 (0.49, 1.46)				1.01 (0.76, 1.34)				0.71 (-3.50, 4.99)			
Methyl-paraben																
Continuous ^d	0.91 (0.83, 1.00)		0.05		0.98 (0.85, 1.12)		0.72		0.96 (0.89, 1.03)		0.24		-0.48 (-1.45, 0.49)		0.33	
T1	1.00	0.09	0.24		1.00	0.92	0.93		1.00	0.12	0.09		0.00	0.24	0.18	
T2	0.70 (0.49, 0.99)				1.12 (0.66, 1.89)				0.81 (0.61, 1.07)				1.62 (-2.59, 5.82)			
T3	0.75 (0.53, 1.06)				1.05 (0.61, 1.82)				0.75 (0.56, 1.00)				-1.98 (-6.02, 2.07)			
Ethyl-paraben																
Continuous ^d	0.99 (0.93, 1.07)		0.88		1.10 (0.99, 1.23)		0.08		1.00 (0.96, 1.06)		0.98		-0.57 (-1.32, 0.19)		0.14	
T1	1.00	0.82	0.53		1.00	0.08	0.05		1.00	0.03	0.38		0.00	0.55	0.28	
T2	1.04 (0.72, 1.49)				1.47 (0.83, 2.60)				1.41 (1.06, 1.87)				-0.35 (-4.56, 3.87)			
T3	1.12 (0.78, 1.62)				1.91 (1.08, 3.37)				1.03 (0.76, 1.39)				-2.11 (-6.26, 2.04)			
Propyl-paraben																
Continuous ^d	0.97 (0.90, 1.04)		0.40		1.01 (0.90, 1.14)		0.83		0.96 (0.91, 1.03)		0.25		-0.30 (-1.11, 0.52)		0.47	
T1	1.00	0.71	0.57		1.00	0.75	0.97		1.00	0.34	0.17		0.00	0.91	0.86	
T2	1.09 (0.77, 1.55)				1.22 (0.72, 2.07)				0.91 (0.69, 1.20)				-0.91 (-5.03, 3.20)			
T3	0.94 (0.66, 1.35)				1.08 (0.63, 1.86)				0.81 (0.61, 1.07)				-0.57 (-4.71, 3.56)			
Butyl-paraben																
Continuous ^d	0.97 (0.90, 1.05)		0.45		1.00 (0.89, 1.11)		0.93		0.98 (0.93, 1.04)		0.56		-0.43 (-1.23, 0.37)		0.29	
T1	1.00	0.34	0.35		1.00	0.67	0.85		1.00	0.08	0.08		0.00	0.47	0.34	
T2	1.21 (0.85, 1.73)				1.28 (0.75, 2.19)				1.20 (0.90, 1.60)				-1.72 (-5.85, 2.41)			
T3	0.94 (0.64, 1.38)				1.19 (0.67, 2.12)				0.87 (0.64, 1.17)				-2.56 (-6.74, 1.62)			
ΣParabens																
Continuous ^d	0.91 (0.83, 1.00)		0.04		0.98 (0.85, 1.13)		0.79		0.96 (0.89, 1.03)		0.26		-0.45 (-1.43, 0.52)		0.36	
T1	1.00	0.15	0.16		1.00	0.82	0.67		1.00	0.18	0.27		0.00	0.52	0.31	
T2	0.75 (0.53, 1.07)				1.10 (0.66, 1.83)				0.79 (0.60, 1.05)				0.73 (-3.48, 4.95)			
T3	0.73 (0.51, 1.05)				0.92 (0.53, 1.60)				0.81 (0.61, 1.07)				-1.63 (-5.70, 2.44)			

HR = hazard ratio; FEV,%= forced expiratory volume in 1 second expressed in percent predicted; CI = confidence interval; ΣDichlorophenols = molar sum of 2-Dichlorophenols (2,4-, 2,5-dichlorophenols); ΣParabens = molar sum of parabens (Methyl-, Ethyl-, Propyl-, Butyl-parabens).

^a Models adjusted for centre, residence area, parental history of asthma or allergies, maternal ethnicity, maximal parental education level, passive smoking during pregnancy, postnatal passive smoking, older siblings, day-care. Missing values in covariates were imputed using the MICE multiple imputation method (100 imputations were performed) ^b additionally adjusted for child's height and age.

^c Standardized for urine sampling conditions (creatinine level, day and hour of sampling, gestational age, storage duration at room temperature and year of analysis), as detailed in Mortamais et al. (2012).

^d Estimates for 1 unit increase in ln-transformed standardized concentration.

^e p-values of heterogeneity test.

Italicized p-values are p-values of monotonic trend test.

Table S7. Adjusted associations between pregnancy phthalate metabolites standardized concentrations and respiratory outcomes (n=447) and FEV₁% (n=171) in boys from non-smoking mothers.

Phthalate ^c	Wheezing (until age 5y) ^a			Asthma diagnosis (until age 5y) ^a			Bronchiolitis/Bronchitis (until age 3y) ^a			FEV ₁ % ^b		
	N = 447			N = 447			N = 447			N = 171		
	HR (95% CI)	P _{het} ^e	p-value	HR (95% CI)	P _{het} ^e	p-value	HR (95% CI)	P _{het} ^e	p-value	beta (95% CI)	P _{het} ^e	p-value
ΣLMW												
Continuous ^d	0.93 (0.78, 1.11)			1.01 (0.78, 1.32)			1.05 (0.91, 1.21)			-0.13 (-2.36, 2.10)		
T1	1.00	0.74	0.89	1.00	0.05	0.90	1.00	0.64	0.36	0.00	0.64	0.91
T2	1.15 (0.81, 1.64)			1.84 (1.09, 3.10)			1.07 (0.80, 1.43)			-0.56 (-4.77, 3.65)		
T3	1.06 (0.74, 1.52)			1.18 (0.66, 2.12)			1.15 (0.86, 1.52)			-1.93 (-6.02, 2.17)		
MEP												
Continuous ^d	0.97 (0.84, 1.11)			1.10 (0.90, 1.34)			1.03 (0.92, 1.15)			-0.37 (-2.11, 1.37)		
T1	1.00	0.97	0.87	1.00	0.55	0.35	1.00	0.92	0.68	0.00	0.77	0.67
T2	0.98 (0.69, 1.39)			1.25 (0.72, 2.15)			1.01 (0.76, 1.35)			0.81 (-3.26, 4.50)		
T3	1.02 (0.71, 1.46)			1.34 (0.78, 2.32)			1.06 (0.80, 1.41)			-0.69 (-4.91, 3.53)		
MnBP												
Continuous ^d	1.04 (0.91, 1.19)			1.01 (0.83, 1.24)			1.03 (0.92, 1.15)			0.22 (-1.36, 1.79)		
T1	1.00	0.73	0.47	1.00	0.71	0.91	1.00	0.93	0.84	0.00	0.93	0.79
T2	0.97 (0.67, 1.39)			1.23 (0.73, 2.08)			0.95 (0.72, 1.27)			0.09 (-4.14, 4.31)		
T3	1.11 (0.78, 1.58)			1.04 (0.60, 1.81)			0.96 (0.72, 1.27)			-0.64 (-4.88, 3.60)		
MiBP												
Continuous ^d	0.95 (0.79, 1.14)			1.01 (0.77, 1.33)			0.98 (0.84, 1.14)			-0.51 (-2.62, 1.60)		
T1	1.00	0.83	0.94	1.00	0.64	0.71	1.00	1.00	0.95	0.00	0.46	0.23
T2	0.89 (0.62, 1.29)			1.21 (0.71, 2.06)			1.00 (0.75, 1.34)			-0.11 (-4.34, 4.11)		
T3	0.96 (0.67, 1.37)			0.95 (0.55, 1.64)			1.01 (0.75, 1.35)			-2.28 (-6.36, 1.80)		
ΣHMW												
Continuous ^d	1.08 (0.90, 1.29)			1.12 (0.84, 1.48)			0.92 (0.78, 1.07)			-0.79 (-2.99, 1.41)		
T1	1.00	0.28	0.64	1.00	0.64	0.45	1.00	0.85	0.68	0.00	0.65	0.61
T2	1.34 (0.93, 1.92)			0.91 (0.53, 1.58)			1.04 (0.78, 1.37)			-1.96 (-6.19, 2.27)		
T3	1.16 (0.80, 1.68)			1.17 (0.69, 1.97)			0.95 (0.71, 1.27)			-1.23 (-5.39, 2.93)		
MCPP												
Continuous ^d	0.98 (0.82, 1.17)			0.94 (0.72, 1.23)			0.92 (0.79, 1.06)			0.08 (-2.08, 2.25)		
T1	1.00	0.99	0.90	1.00	0.87	0.62	1.00	0.18	0.14	0.00	0.75	0.83
T2	0.99 (0.69, 1.40)			0.93 (0.55, 1.58)			1.11 (0.84, 1.46)			-0.95 (-5.14, 3.23)		
T3	0.98 (0.68, 1.40)			0.87 (0.50, 1.49)			0.85 (0.63, 1.14)			0.28 (-3.87, 4.83)		
MBzP												
Continuous ^d	1.01 (0.87, 1.17)			1.22 (0.99, 1.51)			0.96 (0.85, 1.08)			0.20 (-1.62, 2.01)		
T1	1.00	0.80	1.00	1.00	0.28	0.38	1.00	0.67	0.39	0.00	0.10	0.83
T2	1.13 (0.78, 1.62)			1.56 (0.88, 2.77)			1.00 (0.75, 1.33)			-4.34 (-8.55, -0.13)		
T3	1.03 (0.72, 1.49)			1.42 (0.82, 2.47)			0.89 (0.67, 1.19)			-3.39 (-7.52, 0.73)		
MCNP												
Continuous ^d	1.04 (0.90, 1.19)			0.99 (0.80, 1.22)			0.93 (0.82, 1.04)			1.36 (-0.28, 3.01)		
T1	1.00	0.70	0.40	1.00	0.24	0.41	1.00	0.95	0.88	0.00	0.09	0.19
T2	1.02 (0.71, 1.46)			1.60 (0.92, 2.80)			0.95 (0.72, 1.27)			-2.71 (6.83, 1.41)		
T3	1.15 (0.81, 1.64)			1.43 (0.82, 2.49)			0.97 (0.73, 1.28)			1.97 (-2.21, 6.14)		
MCOP												
Continuous ^d	0.97 (0.82, 1.16)			0.95 (0.73, 1.22)			1.06 (0.93, 1.22)			-1.29 (-3.10, 0.53)		
T1	1.00	0.50	0.31	1.00	0.62	0.67	1.00	0.33	0.82	0.00	0.46	0.37
T2	0.86 (0.60, 1.22)			0.76 (0.44, 1.31)			1.21 (0.91, 1.61)			-2.54 (-6.75, 1.68)		
T3	0.81 (0.57, 1.16)			0.89 (0.53, 1.50)			1.01 (0.75, 1.36)			-1.89 (-6.03, 2.25)		
MEHHP												
Continuous ^d	1.09 (0.92, 1.28)			1.04 (0.80, 1.34)			0.97 (0.85, 1.11)			-0.67 (-2.57, 1.23)		
T1	1.00	0.37	0.21	1.00	0.93	0.85	1.00	0.89	0.94	0.00	0.63	0.63
T2	1.22 (0.84, 1.75)			1.07 (0.63, 1.83)			1.06 (0.80, 1.41)			-1.98 (-6.04, 2.08)		
T3	1.29 (0.90, 1.85)			0.97 (0.56, 1.67)			1.00 (0.75, 1.34)			-1.14 (-5.37, 3.10)		
MEOHP												
Continuous ^d	1.08 (0.92, 1.28)			1.05 (0.81, 1.36)			0.95 (0.83, 1.09)			-1.06 (-3.01, 0.89)		
T1	1.00	0.48	0.31	1.00	0.69	0.85	1.00	0.95	0.92	0.00	0.43	0.21
T2	1.20 (0.83, 1.72)			0.81 (0.47, 1.40)			1.05 (0.79, 1.39)			-2.04 (-6.17, 2.10)		
T3	1.24 (0.86, 1.78)			1.00 (0.59, 1.68)			1.02 (0.77, 1.36)			-2.63 (-6.87, 1.60)		
MECPP												
Continuous ^d	1.05 (0.88, 1.25)			1.07 (0.82, 1.41)			0.95 (0.82, 1.10)			-1.15 (-3.17, 0.86)		
T1	1.00	0.40	0.36	1.00	0.97	0.80	1.00	0.96	0.79	0.00	0.12	0.04
T2	1.26 (0.88, 1.81)			1.04 (0.60, 1.79)			1.00 (0.75, 1.33)			-2.35 (-6.48, 1.78)		
T3	1.23 (0.85, 1.77)			1.07 (0.63, 1.83)			1.04 (0.78, 1.38)			-4.24 (-8.30, -0.18)		
MEHP												
Continuous ^d	1.05 (0.91, 1.22)			1.00 (0.81, 1.25)			0.95 (0.84, 1.06)			-1.08 (-2.70, 0.53)		
T1	1.00	0.68	0.40	1.00	0.69	0.71	1.00	0.70	0.54	0.00	0.49	0.29
T2	1.09 (0.76, 1.57)			0.84 (0.49, 1.44)			0.90 (0.68, 1.20)			0.25 (-3.94, 4.43)		
T3	1.17 (0.82, 1.67)			1.05 (0.63, 1.76)			0.90 (0.68, 1.20)			-2.05 (-6.20, 2.11)		
ΣDEHP												
Continuous ^d	1.07 (0.90, 1.28)			1.05 (0.80, 1.37)			0.95 (0.82, 1.09)			-1.04 (-3.03, 0.96)		
T1	1.00	0.30	0.40	1.00	0.97	0.93	1.00	0.89	0.90	0.00	0.44	0.34
T2	1.32 (0.92, 1.90)			0.95 (0.56, 1.63)			1.06 (0.80, 1.41)			-2.53 (-6.61, 1.54)		
T3	1.23 (0.85, 1.77)			1.01 (0.60, 1.71)			0.99 (0.75, 1.33)			-1.98 (-6.15, 2.19)		

HR = hazard ratio; FEV₁% = forced expiratory volume in 1 second expressed in percent predicted; CI = confidence interval; ΣLMW = molar sum of Low Molecular Weight phthalates (MEP, MnBP, MiBP); ΣHMW = molar sum of High Molecular Weight phthalates (MCPP, MBzP, MCNP, MCOP, MEHHP, MEOHP, MECPP, MEHP); ΣDEHP = molar sum of di(2-ethylhexyl) phthalate metabolites (MEHHP, MEOHP, MECPP, MEHP). Parent compounds and associated metabolites are detailed in Table S1 (Supplemental material).

^a Models adjusted for centre, residence area, parental history of asthma or allergies, maternal ethnicity, maximal parental education level, passive smoking during pregnancy, postnatal passive smoking, older siblings, day-care. Missing values in covariates were imputed using the MICE multiple imputation method (100 imputations were performed) ^b additionally adjusted for child's height and age.

^c Standardized for urine sampling conditions (creatinine level, day and hour of sampling, gestational age, storage duration at room temperature and year of analysis), as detailed in Mortamais et al. (2012).

^d Estimates for 1 unit increase in ln-transformed standardized concentration.

^e p-values of heterogeneity test.

Italicized p-values are p-values of monotonic trend test.

Table S8. Adjusted associations between pregnancy phenols standardized concentrations and respiratory outcomes (n=470) and FEV₁% (n=185) in boys from non-asthmatic parents.

Phenol ^c	Wheezing (until age 5y) ^a			Asthma diagnosis (until age 5y) ^a			Bronchiolitis/Bronchitis (until age 3y) ^a			FEV ₁ % ^b						
	HR (95% CI)	N = 470	p _{het} ^e	p-value	HR (95% CI)	N = 470	p _{het} ^e	p-value	HR (95% CI)	N = 470	p _{het} ^e	p-value	beta (95% CI)	N = 185	p _{het} ^e	p-value
2,4-Dichlorophenol																
Continuous ^d	1.06 (0.94, 1.20)		0.36		0.95 (0.78, 1.16)		0.62		0.95 (0.86, 1.06)		0.38		-0.30 (-1.77, 1.17)		0.69	
T1	1.00	0.73	0.91		1.00	0.34	0.38		1.00	0.52	0.34		0.00	0.91	0.76	
T2	1.15 (0.81, 1.63)				1.28 (0.76, 2.14)				1.06 (0.80, 1.39)				-0.73 (-4.73, 3.28)			
T3	1.06 (0.75, 1.51)				0.86 (0.49, 1.49)				0.90 (0.69, 1.18)				-0.84 (-4.81, 3.14)			
2,5-Dichlorophenol																
Continuous ^d	1.08 (0.99, 1.18)		0.08		1.01 (0.88, 1.16)		0.86		0.99 (0.92, 1.07)		0.86		-0.02 (-1.00, 1.03)		0.97	
T1	1.00	0.11	0.22		1.00	0.23	0.43		1.00	0.76	0.58		0.00	0.96	0.78	
T2	1.42 (0.99, 2.03)				1.59 (0.91, 2.76)				1.08 (0.82, 1.44)				0.06 (-3.91, 4.03)			
T3	1.40 (0.98, 2.00)				1.46 (0.84, 2.54)				1.11 (0.84, 1.46)				0.50 (-3.42, 4.42)			
ΣDichlorophenols																
Continuous ^d	1.08 (0.99, 1.18)		0.10		1.00 (0.87, 1.16)		0.95		0.99 (0.92, 1.07)		0.80		-0.02 (-1.09, 1.04)		0.97	
T1	1.00	0.11	0.16		1.00	0.20	0.28		1.00	0.79	0.49		0.00	0.99	0.91	
T2	1.39 (0.97, 1.99)				1.57 (0.90, 2.75)				1.02 (0.77, 1.35)				0.21 (-3.77, 4.19)			
T3	1.42 (1.00, 2.02)				1.54 (0.89, 2.68)				1.10 (0.83, 1.45)				0.27 (-3.67, 4.21)			
Bisphenol A																
Continuous ^d	0.94 (0.77, 1.15)		0.56		1.25 (0.93, 1.66)		0.14		1.11 (0.95, 1.29)		0.18		-1.40 (-3.47, 0.67)		0.18	
T1	1.00	0.86	0.84		1.00	0.47	0.22		1.00	0.50	0.26		0.00	0.45	0.25	
T2	0.91 (0.64, 1.28)				1.12 (0.63, 1.98)				1.10 (0.83, 1.45)				-1.79 (-5.69, 2.10)			
T3	0.95 (0.66, 1.34)				1.38 (0.80, 2.39)				1.18 (0.89, 1.57)				-2.49 (-6.47, 1.49)			
Benzophenone-3																
Continuous ^d	0.95 (0.87, 1.03)		0.21		0.96 (0.84, 1.10)		0.57		1.00 (0.93, 1.07)		0.97		-0.80 (-1.82, 0.22)		0.12	
T1	1.00	0.13	0.05		1.00	0.36	0.17		1.00	0.78	0.83		0.00	0.36	0.16	
T2	0.89 (0.63, 1.24)				0.86 (0.52, 1.43)				0.91 (0.69, 1.19)				-0.75 (-4.65, 3.14)			
T3	0.69 (0.48, 0.99)				0.67 (0.38, 1.16)				0.93 (0.71, 1.24)				-2.73 (-6.61, 1.15)			
Triclosan																
Continuous ^d	0.99 (0.93, 1.04)		0.62		0.99 (0.91, 1.08)		0.89		0.99 (0.95, 1.04)		0.70		0.07 (-0.57, 0.71)		0.83	
T1	1.00	0.97	0.80		1.00	1.00	0.93		1.00	0.94	0.73		0.00	0.99	0.94	
T2	0.98 (0.70, 1.39)				1.00 (0.59, 1.70)				0.99 (0.75, 1.30)				-0.16 (-4.11, 3.79)			
T3	0.96 (0.68, 1.35)				0.98 (0.58, 1.67)				0.95 (0.73, 1.25)				0.18 (-4.07, 3.70)			
Methyl-paraben																
Continuous ^d	0.93 (0.85, 1.02)		0.11		1.02 (0.89, 1.17)		0.75		0.94 (0.87, 1.01)		0.10		-0.46 (-1.40, 0.49)		0.34	
T1	1.00	0.09	0.16		1.00	0.87	0.94		1.00	0.03	0.01		0.00	0.18	0.31	
T2	0.71 (0.50, 1.00)				1.14 (0.68, 1.91)				0.81 (0.62, 1.06)				2.44 (-1.47, 6.35)			
T3	0.73 (0.52, 1.03)				1.01 (0.58, 1.75)				0.68 (0.52, 0.90)				-1.21 (-5.02, 2.59)			
Ethyl-paraben																
Continuous ^d	1.02 (0.95, 1.09)		0.58		1.11 (0.99, 1.23)		0.08		0.99 (0.94, 1.04)		0.69		-0.85 (-1.57, -0.13)		0.02	
T1	1.00	0.49	0.82		1.00	0.08	0.17		1.00	0.001	0.08		0.00	0.10	0.04	
T2	1.23 (0.87, 1.75)				1.80 (1.03, 3.16)				1.51 (1.15, 1.98)				-1.98 (-5.79, 1.83)			
T3	1.13 (0.79, 1.61)				1.82 (1.02, 3.25)				0.95 (0.71, 1.26)				-4.28 (-8.15, -0.41)			
Propyl-paraben																
Continuous ^d	0.94 (0.88, 1.02)		0.12		1.00 (0.90, 1.12)		0.95		0.96 (0.91, 1.02)		0.19		-0.19 (-0.98, 0.60)		0.63	
T1	1.00	0.62	0.45		1.00	0.91	0.75		1.00	0.27	0.22		0.00	0.46	0.46	
T2	0.88 (0.63, 1.24)				0.92 (0.55, 1.61)				0.84 (0.64, 1.11)				1.80 (-2.06, 5.66)			
T3	0.85 (0.60, 1.20)				1.06 (0.62, 1.81)				0.81 (0.61, 1.06)				-0.62 (-4.52, 3.28)			
Butyl-paraben																
Continuous ^d	0.99 (0.92, 1.06)		0.77		0.99 (0.88, 1.11)		0.87		0.98 (0.93, 1.03)		0.45		-0.91 (-1.68, -0.14)		0.02	
T1	1.00	0.46	0.31		1.00	0.98	0.84		1.00	0.004	0.01		0.00	0.15	0.06	
T2	1.11 (0.79, 1.57)				1.00 (0.59, 1.70)				1.26 (0.96, 1.66)				-1.30 (-5.12, 2.52)			
T3	0.89 (0.62, 1.29)				1.05 (0.60, 1.85)				0.79 (0.59, 1.06)				-3.78 (-7.63, 0.07)			
ΣParabens																
Continuous ^d	0.93 (0.85, 1.01)		0.09		1.02 (0.89, 1.17)		0.79		0.95 (0.88, 1.02)		0.13		-0.48 (-1.43, 0.47)		0.32	
T1	1.00	0.13	0.14		1.00	0.89	0.73		1.00	0.07	0.06		0.00	0.43	0.67	
T2	0.75 (0.54, 1.06)				1.06 (0.64, 1.78)				0.78 (0.60, 1.02)				2.07 (-1.88, 6.01)			
T3	0.73 (0.52, 1.04)				0.93 (0.54, 1.61)				0.74 (0.56, 0.98)				-0.38 (-4.19, 3.44)			

HR = hazard ratio; FEV₁% = forced expiratory volume in 1 second expressed in percent predicted; CI = confidence interval; ΣDichlorophenols = molar sum of 2-Dichlorophenols (2,4-, 2,5-dichlorophenols); ΣParabens = molar sum of parabens (Methyl-, Ethyl-, Propyl-, Butyl-parabens).

^a Models adjusted for centre, residence area, parental history of allergies, maternal ethnicity, maximal parental education level, maternal or passive smoking during pregnancy, postnatal passive smoking, older siblings, day-care. Missing values in covariates were imputed using the MICE multiple imputation method (100 imputations were performed)^b additionally adjusted for child's height and age.

^c Standardized for urine sampling conditions (creatinine level, day and hour of sampling, gestational age, storage duration at room temperature and year of analysis), as detailed in Mortamais et al. (2012).

^d Estimates for 1 unit increase in ln-transformed standardized concentration.

^e p-values of heterogeneity test.

Italicized p-values are p-values of monotonic trend test.

Table S9. Adjusted associations between pregnancy phthalate metabolites standardized concentrations and respiratory outcomes (n=470) and FEV₁% (n=185) in boys from non-asthmatic parents.

Phthalate ^c	Wheezing (until age 5y) ^a			Asthma diagnosis (until age 5y) ^a			Bronchiolitis/Bronchitis (until age 3y) ^a			FEV ₁ % ^b		
	N = 470			N = 470			N = 470			N = 185		
	HR (95% CI)	P _{het} ^e	p-value	HR (95% CI)	P _{het} ^e	p-value	HR (95% CI)	P _{het} ^e	p-value	beta (95% CI)	P _{het} ^e	p-value
ΣLMW												
Continuous ^d	0.90 (0.76, 1.07)	0.42	0.25	0.92 (0.71, 1.20)	0.88	0.55	0.97 (0.85, 1.11)	0.84	0.71	-1.29 (-3.26, 0.68)	0.10	0.20
T1	1.00		0.26	1.00		0.67	1.00		0.61	0.00		0.03
T2	0.85 (0.60, 1.19)			1.04 (0.62, 1.74)			0.94 (0.72, 1.24)			-0.32 (-4.18, 3.54)		
T3	0.80 (0.56, 1.13)			0.90 (0.52, 1.56)			0.92 (0.70, 1.22)			-3.71 (-7.50, -0.07)		
MEP												
Continuous ^d	0.95 (0.83, 1.08)	0.65	0.43	1.01 (0.82, 1.24)	0.80	0.94	0.99 (0.90, 1.10)	0.69	0.91	-1.19 (-2.75, 0.36)	0.43	0.13
T1	1.00		0.35	1.00		0.51	1.00		0.66	0.00		0.26
T2	0.95 (0.67, 1.34)			0.92 (0.54, 1.57)			1.09 (0.83, 1.43)			-2.01 (-5.87, 1.86)		
T3	0.85 (0.60, 1.21)			0.83 (0.48, 1.43)			0.97 (0.73, 1.28)			-2.36 (-6.24, 1.51)		
MnBP												
Continuous ^d	1.00 (0.88, 1.14)	0.97	0.97	0.97 (0.78, 1.19)	0.74	0.74	0.95 (0.85, 1.06)	0.10	0.31	-0.18 (-1.65, 1.30)	0.42	0.81
T1	1.00		0.85	1.00		0.56	1.00		0.34	0.00		0.51
T2	1.04 (0.74, 1.47)			0.85 (0.50, 1.42)			0.75 (0.57, 0.98)			1.76 (-2.20, 5.72)		
T3	1.04 (0.73, 1.49)			0.83 (0.48, 1.42)			0.80 (0.61, 1.06)			-0.72 (-4.75, 3.32)		
MiBP												
Continuous ^d	1.01 (0.85, 1.20)	0.88	0.88	1.15 (0.87, 1.51)	0.98	0.33	1.08 (0.94, 1.24)	0.86	0.29	-0.77 (-2.68, 1.14)	0.38	0.43
T1	1.00		0.83	1.00		0.97	1.00		0.59	0.00		0.23
T2	0.91 (0.63, 1.30)			1.06 (0.62, 1.80)			1.03 (0.78, 1.37)			0.80 (-3.11, 4.71)		
T3	1.01 (0.71, 1.43)			1.02 (0.60, 1.75)			1.08 (0.82, 1.43)			-1.88 (-5.76, 2.01)		
ΣHMW												
Continuous ^d	1.12 (0.93, 1.34)	0.23	0.23	1.15 (0.86, 1.53)	0.93	0.35	0.95 (0.82, 1.10)	0.55	0.49	-1.31 (-3.47, 0.84)	0.23	0.23
T1	1.00		0.39	1.00		0.81	1.00		0.37	0.00		0.76
T2	1.24 (0.88, 1.76)			1.06 (0.62, 1.80)			0.88 (0.67, 1.16)			-3.33 (-7.18, 0.52)		
T3	1.03 (0.72, 1.47)			0.95 (0.56, 1.64)			0.87 (0.66, 1.14)			-1.46 (-5.36, 2.44)		
MCPP												
Continuous ^d	0.99 (0.84, 1.17)	0.90	0.90	0.97 (0.75, 1.27)	0.98	0.85	0.87 (0.76, 1.00)	0.15	0.04	-0.28 (-2.28, 1.72)	0.23	0.78
T1	1.00		0.56	1.00		0.86	1.00		0.08	0.00		0.50
T2	1.18 (0.83, 1.65)			0.98 (0.57, 1.66)			1.05 (0.81, 1.38)			-2.66 (-6.47, 1.15)		
T3	1.00 (0.70, 1.43)			0.95 (0.56, 1.63)			0.81 (0.61, 1.07)			0.38 (-3.51, 4.27)		
MBzP												
Continuous ^d	1.01 (0.87, 1.16)	0.75	0.95	1.16 (0.92, 1.45)	0.62	0.20	1.00 (0.89, 1.12)	0.97	0.98	-0.82 (-2.60, 0.95)	0.13	0.36
T1	1.00		0.53	1.00		0.95	1.00		0.96	0.00		0.05
T2	1.04 (0.74, 1.48)			1.29 (0.75, 2.23)			0.97 (0.74, 1.28)			-2.00 (-5.91, 1.92)		
T3	0.92 (0.64, 1.31)			1.08 (0.61, 1.89)			1.00 (0.76, 1.31)			-3.92 (-7.77, -0.08)		
MCNP												
Continuous ^d	1.12 (0.98, 1.28)	0.31	0.09	1.12 (0.92, 1.36)	0.60	0.27	0.98 (0.88, 1.09)	0.96	0.69	-0.06 (-1.74, 1.62)	0.51	0.94
T1	1.00		0.15	1.00		0.46	1.00		0.98	0.00		0.61
T2	1.16 (0.81, 1.65)			1.27 (0.73, 2.20)			1.04 (0.79, 1.37)			-2.14 (-6.02, 1.73)		
T3	1.31 (0.93, 1.85)			1.29 (0.75, 2.21)			1.02 (0.77, 1.33)			-1.82 (-5.79, 2.15)		
MCOP												
Continuous ^d	1.07 (0.91, 1.27)	0.68	0.40	1.09 (0.85, 1.38)	0.81	0.50	1.15 (1.02, 1.31)	0.63	0.03	-1.78 (-3.50, -0.06)	0.11	0.04
T1	1.00		0.69	1.00		0.66	1.00		0.66	0.00		0.04
T2	1.12 (0.79, 1.58)			0.91 (0.53, 1.57)			1.14 (0.87, 1.50)			-0.87 (-4.74, 3.00)		
T3	0.96 (0.68, 1.37)			1.09 (0.65, 1.85)			1.09 (0.83, 1.44)			-3.91 (-7.77, -0.05)		
MEHHP												
Continuous ^d	1.14 (0.96, 1.36)	0.21	0.13	1.10 (0.85, 1.42)	0.37	0.48	1.00 (0.88, 1.14)	0.62	0.98	-0.86 (-2.70, 0.97)	0.22	0.35
T1	1.00		0.58	1.00		0.76	1.00		0.82	0.00		0.75
T2	1.37 (0.97, 1.95)			1.38 (0.81, 2.35)			1.12 (0.85, 1.47)			-3.20 (-6.98, 0.58)		
T3	1.18 (0.82, 1.69)			1.00 (0.57, 1.74)			0.99 (0.75, 1.31)			-0.79 (-4.73, 3.15)		
MEOHP												
Continuous ^d	1.13 (0.95, 1.33)	0.09	0.16	1.08 (0.83, 1.41)	0.72	0.56	0.97 (0.85, 1.11)	0.25	0.68	-1.25 (-3.13, 0.63)	0.10	0.19
T1	1.00		0.66	1.00		0.54	1.00		0.62	0.00		0.51
T2	1.46 (1.03, 2.07)			1.07 (0.64, 1.81)			1.19 (0.91, 1.57)			-4.19 (-8.02, -0.35)		
T3	1.15 (0.80, 1.66)			0.86 (0.50, 1.49)			0.96 (0.73, 1.28)			-1.74 (-5.62, 2.13)		
MECPP												
Continuous ^d	1.13 (0.95, 1.34)	0.11	0.17	1.13 (0.87, 1.49)	0.78	0.36	0.95 (0.82, 1.10)	0.91	0.48	-1.21 (-3.22, 0.80)	0.28	0.24
T1	1.00		0.47	1.00		0.92	1.00		0.66	0.00		0.52
T2	1.45 (1.02, 2.06)			1.21 (0.70, 2.07)			0.98 (0.75, 1.29)			-3.18 (-7.10, 0.74)		
T3	1.23 (0.86, 1.76)			1.07 (0.62, 1.85)			0.94 (0.72, 1.24)			-1.91 (-5.81, 2.00)		
MEHP												
Continuous ^d	1.04 (0.91, 1.20)	0.39	0.55	1.06 (0.86, 1.32)	0.31	0.57	0.93 (0.83, 1.04)	0.25	0.21	-0.81 (-2.32, 0.70)	0.69	0.29
T1	1.00		0.19	1.00		0.17	1.00		0.75	0.00		0.39
T2	1.00 (0.70, 1.43)			0.93 (0.53, 1.64)			0.81 (0.62, 1.07)			-0.34 (-4.21, 3.53)		
T3	1.23 (0.87, 1.73)			1.36 (0.81, 2.81)			0.99 (0.76, 1.30)			-1.61 (-5.51, 2.29)		
ΣDEHP												
Continuous ^d	1.13 (0.95, 1.34)	0.10	0.18	1.10 (0.84, 1.45)	0.66	0.48	0.96 (0.83, 1.11)	0.69	0.57	-1.14 (-3.10, 0.82)	0.16	0.25
T1	1.00		0.78	1.00		0.62	1.00		0.80	0.00		0.70
T2	1.45 (1.02, 2.07)			1.16 (0.68, 1.98)			1.10 (0.84, 1.45)			-3.37 (-7.23, 0.48)		
T3	1.14 (0.79, 1.63)			0.91 (0.53, 1.57)			0.99 (0.75, 1.30)			-0.30 (-4.21, 3.60)		

^a Models adjusted for centre, residence area, parental history of allergies, maternal ethnicity, maximal parental education level, maternal or passive smoking during pregnancy, postnatal passive smoking, older siblings, day-care. Missing values in covariates were imputed using the MICE multiple imputation method (100 imputations were performed) ^b additionally adjusted for child's height and age. ^c Standardized for urine sampling conditions (creatinine level, day and hour of sampling, gestational age, storage duration at room temperature and year of analysis), as detailed in Mortamais et al. (2012). ^d Estimates for 1 unit increase in ln-transformed standardized concentration. ^e p-values of heterogeneity test. Italicized p-values are p-values of monotonic trend test.

HR = hazard ratio; FEV₁% = forced expiratory volume in 1 second expressed in percent predicted; CI = confidence interval; ΣLMW = molar sum of Low Molecular Weight phthalates (MEP, MnBP, MiBP); ΣHMW = molar sum of High Molecular Weight phthalates (MCPP, MBzP, MCNP, MCOP, MEHHP, MEOHP, MECPP, MEHP); ΣDEHP = molar sum of di(2-ethylhexyl) phthalate metabolites (MEHHP, MEOHP, MECPP, MEHP). Parent compounds and associated metabolites are detailed in Table S1 (Supplemental material)

Table S10. Adjusted associations between pregnancy phenols standardized concentrations and respiratory outcomes (n=562) and FEV₁% (n=217) in full-term boys.

Phenol ^c	Wheezing (until age 5y) ^a			Asthma diagnosis (until age 5y) ^a			Bronchiolitis/Bronchitis (until age 3y) ^a			FEV ₁ % ^b						
	HR (95% CI)	N = 562	p _{het} ^e	p-value	HR (95% CI)	N = 562	p _{het} ^e	p-value	HR (95% CI)	N = 562	p _{het} ^e	p-value	beta (95% CI)	N = 217	p _{het} ^e	p-value
2,4-Dichlorophenol																
Continuous ^d	1.04 (0.93, 1.17)			0.45	1.07 (0.90, 1.27)			0.45	0.98 (0.89, 1.08)			0.63	0.62 (-0.69, 1.93)		0.35	
T1	1.00	0.38	0.97		1.00	0.28	0.91		1.00	0.39	0.42		0.00	0.62	0.95	
T2	1.24 (0.90, 1.70)				1.45 (0.91, 2.31)				1.12 (0.87, 1.44)				1.83 (-1.91, 5.57)			
T3	1.06 (0.77, 1.46)				1.14 (0.70, 1.86)				0.94 (0.73, 1.21)				0.67 (-2.93, 4.26)			
2,5-Dichlorophenol																
Continuous ^d	1.07 (0.99, 1.16)			0.08	1.07 (0.95, 1.20)			0.25	1.00 (0.94, 1.07)			1.00	0.27 (-0.62, 1.16)		0.55	
T1	1.00	0.01	0.19		1.00	0.20	0.20		1.00	0.65	0.57		0.00	0.93	0.80	
T2	1.68 (1.21, 2.33)				1.45 (0.89, 2.35)				0.92 (0.71, 1.19)				-0.44 (-4.13, 3.24)			
T3	1.49 (1.07, 2.07)				1.50 (0.93, 2.43)				1.03 (0.80, 1.33)				0.25 (-3.36, 3.86)			
ΣDichlorophenols																
Continuous ^d	1.07 (0.99, 1.16)			0.10	1.07 (0.95, 1.21)			0.27	1.00 (0.93, 1.07)			0.97	0.32 (-0.62, 1.26)		0.50	
T1	1.00	0.06	0.18		1.00	0.21	0.19		1.00	0.71	0.42		0.00	0.87	0.89	
T2	1.44 (1.04, 1.99)				1.42 (0.87, 2.30)				1.00 (0.77, 1.29)				-0.89 (-4.61, 2.82)			
T3	1.40 (1.01, 1.93)				1.51 (0.93, 2.44)				1.10 (0.85, 1.41)				-0.08 (-3.68, 3.53)			
Bisphenol A																
Continuous ^d	0.98 (0.83, 1.16)			0.83	1.19 (0.94, 1.51)			0.15	1.14 (0.99, 1.31)			0.06	-0.66 (-2.53, 1.20)		0.48	
T1	1.00	1.00	0.98		1.00	0.45	0.21		1.00	0.39	0.18		0.00	0.59	0.63	
T2	1.01 (0.74, 1.38)				1.07 (0.65, 1.76)				1.10 (0.86, 1.42)				-1.85 (-5.45, 1.76)			
T3	1.01 (0.73, 1.39)				1.32 (0.83, 2.12)				1.20 (0.93, 1.54)				-1.28 (-4.98, 2.42)			
Benzophenone-3																
Continuous ^d	0.92 (0.85, 1.00)			0.06	0.94 (0.83, 1.06)			0.30	1.00 (0.93, 1.06)			0.90	-0.32 (-1.29, 0.65)		0.69	
T1	1.00	0.03	0.01		1.00	0.11	0.07		1.00	0.72	0.79		0.00	0.89	0.75	
T2	0.88 (0.65, 1.20)				0.76 (0.49, 1.20)				0.90 (0.70, 1.16)				-0.71 (-4.33, 2.91)			
T3	0.65 (0.47, 0.90)				0.59 (0.36, 0.97)				0.93 (0.72, 1.20)				-0.78 (-4.34, 2.78)			
Triclosan																
Continuous ^d	0.98 (0.94, 1.04)			0.62	0.98 (0.91, 1.06)			0.63	1.00 (0.96, 1.04)			0.94	0.10 (-0.48, 0.69)		0.73	
T1	1.00	0.88	0.63		1.00	0.88	0.75		1.00	0.98	0.95		0.00	0.91	0.82	
T2	0.97 (0.71, 1.32)				1.09 (0.69, 1.72)				1.02 (0.80, 1.31)				0.52 (-3.04, 4.08)			
T3	0.92 (0.68, 1.26)				0.97 (0.60, 1.55)				1.00 (0.78, 1.29)				-0.25 (-3.88, 3.38)			
Methyl-paraben																
Continuous ^d	0.93 (0.85, 1.01)			0.07	1.01 (0.89, 1.14)			0.93	0.95 (0.89, 1.02)			0.14	-0.42 (-1.29, 0.44)		0.33	
T1	1.00	0.08	0.14		1.00	0.96	0.99		1.00	0.06	0.03		0.00	0.26	0.22	
T2	0.74 (0.54, 1.00)				0.94 (0.59, 1.49)				0.85 (0.66, 1.08)				1.57 (-2.08, 5.22)			
T3	0.74 (0.54, 1.01)				0.99 (0.61, 1.59)				0.73 (0.57, 0.95)				-1.51 (-5.03, 2.01)			
Ethyl-paraben																
Continuous ^d	1.01 (0.95, 1.07)			0.86	1.10 (1.00, 1.22)			0.04	0.99 (0.95, 1.04)			0.80	-0.52 (-1.19, 0.15)		0.13	
T1	1.00	0.65	0.83		1.00	0.05	0.10		1.00	0.01	0.29		0.00	0.53	0.31	
T2	1.16 (0.85, 1.59)				1.67 (1.02, 2.74)				1.38 (1.07, 1.78)				-1.05 (-4.65, 2.55)			
T3	1.10 (0.79, 1.51)				1.79 (1.08, 2.98)				1.01 (0.78, 1.31)				-2.05 (-5.64, 1.54)			
Propyl-paraben																
Continuous ^d	0.95 (0.89, 1.02)			0.18	0.99 (0.89, 1.09)			0.79	0.97 (0.92, 1.03)			0.29	-0.18 (-0.91, 0.56)		0.63	
T1	1.00	0.24	0.31		1.00	0.72	0.72		1.00	0.37	0.22		0.00	0.83	0.55	
T2	0.79 (0.58, 1.08)				0.83 (0.52, 1.32)				0.90 (0.70, 1.15)				0.05 (-3.56, 3.66)			
T3	0.80 (0.58, 1.09)				0.87 (0.54, 1.40)				0.84 (0.65, 1.08)				-0.95 (-4.53, 2.63)			
Butyl-paraben																
Continuous ^d	0.98 (0.92, 1.05)			0.60	1.00 (0.90, 1.10)			0.95	0.99 (0.94, 1.04)			0.73	-0.36 (-1.07, 0.35)		0.32	
T1	1.00	0.12	0.13		1.00	0.58	0.78		1.00	0.02	0.03		0.00	0.47	0.53	
T2	1.23 (0.90, 1.67)				1.28 (0.80, 2.06)				1.22 (0.95, 1.57)				-1.94 (-5.50, 1.62)			
T3	0.88 (0.63, 1.23)				1.20 (0.72, 1.99)				0.85 (0.65, 1.10)				-1.97 (-5.60, 1.66)			
ΣParabens																
Continuous ^d	0.92 (0.85, 1.00)			0.06	1.01 (0.89, 1.14)			0.93	0.95 (0.89, 1.02)			0.16	-0.42 (-1.28, 0.45)		0.35	
T1	1.00	0.07	0.08		1.00	0.90	0.73		1.00	0.11	0.19		0.00	0.19	0.26	
T2	0.76 (0.56, 1.03)				1.05 (0.66, 1.65)				0.79 (0.62, 1.02)				2.15 (-1.47, 5.78)			
T3	0.72 (0.52, 0.98)				0.94 (0.58, 1.52)				0.80 (0.62, 1.03)				-1.20 (-4.73, 2.32)			

HR = hazard ratio; FEV₁% = forced expiratory volume in 1 second expressed in percent predicted; CI = confidence interval; ΣDichlorophenols = molar sum of 2-Dichlorophenols (2,4-, 2,5-dichlorophenols); ΣParabens = molar sum of parabens (Methyl-, Ethyl-, Propyl-, Butyl-parabens).

^a Models adjusted for centre, residence area, parental history of asthma or allergies, maternal ethnicity, maximal parental education level, maternal or passive smoking during pregnancy, postnatal passive smoking, older siblings, day-care. Missing values in covariates were imputed using the MICE multiple imputation method (100 imputations were performed) ^b additionally adjusted for child's height and age.

^c Standardized for urine sampling conditions (creatinine level, day and hour of sampling, gestational age, storage duration at room temperature and year of analysis), as detailed in Mortamais et al. (2012).

^d Estimates for 1 unit increase in ln-transformed standardized concentration.

^e p-values of heterogeneity test.

Italicized p-values are p-values of monotonic trend test.

Table S11. Adjusted associations between pregnancy phthalate metabolites standardized concentrations and respiratory outcomes (n=562) and FEV₁% (n=217) in full-term boys.

Phthalate ^c	Wheezing (until age 5y) ^a			Asthma diagnosis (until age 5y) ^a			Bronchiolitis/Bronchitis (until age 3y) ^a			FEV ₁ % ^b		
	N = 562			N = 562			N = 562			N = 217		
	HR (95% CI)	p _{het} ^e	p-value	HR (95% CI)	p _{het} ^e	p-value	HR (95% CI)	p _{het} ^e	p-value	beta (95% CI)	p _{het} ^e	p-value
ΣLMW												
Continuous ^d	0.94 (0.81, 1.10)			0.99 (0.79, 1.24)			1.00 (0.88, 1.13)			-0.18 (-1.98, 1.63)		
T1	1.00	0.75	0.58	1.00	0.67	0.92	1.00	0.84	0.72	0.00	0.26	0.85
T2	1.06 (0.77, 1.44)			1.21 (0.77, 1.90)			1.07 (0.83, 1.38)			-0.65 (-4.22, 2.93)		
T3	0.93 (0.68, 1.29)			1.02 (0.63, 1.66)			1.06 (0.82, 1.37)			-2.82 (-6.35, 0.71)		
MEP												
Continuous ^d	0.97 (0.86, 1.10)			1.10 (0.92, 1.31)			1.02 (0.93, 1.12)			-0.01 (-1.46, 1.44)		
T1	1.00	1.00	0.94	1.00	0.51	0.33	1.00	0.60	0.50	0.00	0.99	0.95
T2	1.01 (0.74, 1.38)			0.91 (0.56, 1.48)			1.12 (0.87, 1.44)			0.16 (-3.40, 3.71)		
T3	1.01 (0.74, 1.39)			1.19 (0.75, 1.89)			1.12 (0.86, 1.44)			-0.08 (-3.69, 3.54)		
MnBP												
Continuous ^d	1.03 (0.91, 1.16)			0.93 (0.77, 1.12)			0.97 (0.88, 1.07)			-0.27 (-1.66, 1.12)		
T1	1.00	0.61	0.42	1.00	0.56	0.31	1.00	0.51	0.51	0.00	0.95	0.82
T2	0.95 (0.69, 1.30)			0.87 (0.55, 1.37)			0.87 (0.68, 1.12)			0.27 (-3.33, 3.87)		
T3	1.10 (0.81, 1.51)			0.77 (0.48, 1.24)			0.89 (0.69, 1.15)			-0.33 (-4.00, 3.34)		
MiBP												
Continuous ^d	0.97 (0.83, 1.13)			1.00 (0.79, 1.27)			1.01 (0.89, 1.15)			-1.30 (-3.02, 0.41)		
T1	1.00	0.75	0.96	1.00	0.69	0.53	1.00	0.93	0.85	0.00	0.09	0.03
T2	0.88 (0.64, 1.22)			1.09 (0.69, 1.73)			1.03 (0.80, 1.33)			-0.81 (-4.42, 2.81)		
T3	0.96 (0.70, 1.32)			0.88 (0.54, 1.44)			0.99 (0.76, 1.27)			-3.77 (-7.32, -0.23)		
ΣHMW												
Continuous ^d	1.07 (0.91, 1.26)			1.09 (0.84, 1.40)			0.92 (0.80, 1.05)			-1.03 (-2.90, 0.84)		
T1	1.00	0.30	0.43	1.00	0.91	0.53	1.00	0.60	0.38	0.00	0.24	0.43
T2	1.27 (0.92, 1.73)			1.11 (0.69, 1.78)			0.91 (0.71, 1.17)			-2.99 (-6.51, 0.54)		
T3	1.06 (0.77, 1.46)			1.05 (0.66, 1.69)			0.88 (0.68, 1.14)			-2.04 (-5.62, 1.54)		
MCPP												
Continuous ^d	1.04 (0.89, 1.21)			0.88 (0.69, 1.13)			0.90 (0.79, 1.03)			-0.50 (-2.40, 1.40)		
T1	1.00	0.72	0.46	1.00	0.58	0.30	1.00	0.46	0.30	0.00	0.44	0.89
T2	1.09 (0.79, 1.49)			0.97 (0.61, 1.53)			1.05 (0.82, 1.34)			-2.21 (-5.76, 1.34)		
T3	1.14 (0.83, 1.57)			0.79 (0.48, 1.28)			0.90 (0.69, 1.16)			-0.57 (-4.14, 2.99)		
MBzP												
Continuous ^d	0.99 (0.87, 1.13)			1.13 (0.94, 1.38)			0.96 (0.87, 1.07)			-0.11 (-1.68, 1.45)		
T1	1.00	0.43	0.43	1.00	0.78	0.20	1.00	0.34	0.14	0.00	0.13	0.30
T2	1.13 (0.83, 1.54)			1.19 (0.74, 1.92)			0.96 (0.74, 1.23)			-3.58 (-7.19, 0.03)		
T3	0.92 (0.67, 1.27)			1.07 (0.67, 1.73)			0.83 (0.65, 1.07)			-2.70 (-6.29, 0.89)		
MCNP												
Continuous ^d	1.10 (0.98, 1.25)			1.13 (0.95, 1.34)			1.00 (0.90, 1.10)			0.49 (-0.98, 1.95)		
T1	1.00	0.22	0.17	1.00	0.29	0.24	1.00	0.55	0.66	0.00	0.94	0.89
T2	1.25 (0.91, 1.73)			1.39 (0.85, 2.29)			1.15 (0.89, 1.48)			-0.60 (-4.15, 2.96)		
T3	1.30 (0.95, 1.78)			1.43 (0.88, 2.30)			1.09 (0.85, 1.41)			-0.43 (-3.99, 3.13)		
MCOP												
Continuous ^d	1.04 (0.89, 1.21)			1.03 (0.82, 1.28)			1.11 (0.99, 1.25)			-1.31 (-2.95, 0.34)		
T1	1.00	0.79	0.57	1.00	0.45	0.90	1.00	0.89	0.95	0.00	0.45	0.21
T2	0.92 (0.67, 1.26)			0.75 (0.46, 1.21)			1.06 (0.83, 1.37)			-0.59 (-4.28, 3.09)		
T3	0.90 (0.66, 1.23)			0.97 (0.61, 1.52)			1.02 (0.79, 1.32)			-2.21 (-5.75, 1.34)		
MEHHP												
Continuous ^d	1.06 (0.92, 1.23)			1.01 (0.80, 1.26)			0.96 (0.86, 1.08)			-0.86 (-2.45, 0.73)		
T1	1.00	0.56	0.60	1.00	0.32	0.70	1.00	0.81	0.67	0.00	0.26	0.33
T2	1.19 (0.86, 1.64)			1.34 (0.84, 2.15)			1.04 (0.81, 1.34)			-2.88 (-6.39, 0.64)		
T3	1.12 (0.82, 1.54)			0.98 (0.60, 1.60)			0.96 (0.74, 1.23)			-1.93 (-5.57, 1.72)		
MEOHP												
Continuous ^d	1.07 (0.92, 1.24)			1.01 (0.80, 1.27)			0.94 (0.84, 1.06)			-1.26 (-2.89, 0.37)		
T1	1.00	0.36	0.67	1.00	0.88	0.68	1.00	0.56	0.53	0.00	0.08	0.08
T2	1.26 (0.92, 1.73)			1.03 (0.65, 1.64)			1.08 (0.84, 1.39)			-3.58 (-7.13, -0.04)		
T3	1.11 (0.81, 1.54)			0.92 (0.57, 1.47)			0.94 (0.73, 1.21)			-3.35 (-6.89, 0.20)		
MECPP												
Continuous ^d	1.06 (0.91, 1.24)			1.08 (0.86, 1.38)			0.93 (0.82, 1.06)			-1.31 (-3.06, 0.44)		
T1	1.00	0.14	0.85	1.00	0.44	0.94	1.00	0.92	0.73	0.00	0.12	0.10
T2	1.36 (0.99, 1.85)			1.32 (0.83, 2.11)			1.01 (0.79, 1.30)			-3.12 (-6.67, 0.45)		
T3	1.11 (0.80, 1.53)			1.05 (0.65, 1.72)			0.96 (0.75, 1.24)			-3.35 (-6.91, 0.21)		
MEHP												
Continuous ^d	1.02 (0.90, 1.15)			0.98 (0.81, 1.18)			0.93 (0.84, 1.03)			-0.83 (-2.18, 0.52)		
T1	1.00	0.71	0.41	1.00	0.77	0.48	1.00	0.24	0.65	0.00	0.31	0.16
T2	1.02 (0.74, 1.40)			1.01 (0.63, 1.63)			0.81 (0.63, 1.04)			0.04 (-3.51, 3.58)		
T3	1.13 (0.83, 1.54)			1.17 (0.73, 1.85)			0.91 (0.71, 1.16)			-2.36 (-5.92, 1.20)		
ΣDEHP												
Continuous ^d	1.06 (0.91, 1.24)			1.03 (0.81, 1.31)			0.94 (0.82, 1.06)			-1.18 (-2.88, 0.52)		
T1	1.00	0.23	0.98	1.00	0.60	0.70	1.00	0.84	0.59	0.00	0.16	0.32
T2	1.30 (0.95, 1.78)			1.19 (0.75, 1.91)			1.01 (0.79, 1.30)			-3.41 (-6.94, 0.12)		
T3	1.06 (0.77, 1.47)			0.96 (0.59, 1.55)			0.94 (0.73, 1.21)			-1.99 (-5.56, 1.58)		

HR = hazard ratio; FEV₁% = forced expiratory volume in 1 second expressed in percent predicted; CI = confidence interval; ΣLMW = molar sum of Low Molecular Weight phthalates (MEP, MnBP, MiBP); ΣHMW = molar sum of High Molecular Weight phthalates (MCPP, MBzP, MCNP, MCOP, MEHHP, MEOHP, MECPP, MEHP); ΣDEHP = molar sum of di(2-ethylhexyl) phthalate metabolites (MEHHP, MEOHP, MECPP, MEHP). Parent compounds and associated metabolites are detailed in Table S1 (Supplemental material).

^a Models adjusted for centre, residence area, parental history of asthma or allergies, maternal ethnicity, maximal parental education level, maternal or passive smoking during pregnancy, postnatal passive smoking, older siblings, day-care. Missing values in covariates were imputed using the MICE multiple imputation method (100 imputations were performed) ^b additionally adjusted for child's height and age.

^c Standardized for urine sampling conditions (creatinine level, day and hour of sampling, gestational age, storage duration at room temperature and year of analysis), as detailed in Mortamais et al. (2012).

^d Estimates for 1 unit increase in ln-transformed standardized concentration.

^e p-values of heterogeneity test.

Italicized p-values are p-values of monotonic trend test.




Figure S1. Occurrence of doctor-diagnosed asthma (A), wheezing (B) and bronchiolitis/bronchitis (C), Kaplan-Meier estimates.